Bronfman E.L. Rothschild L.P. decreased its position in CVS Health (NYSE:CVS) by 16.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,809 shares of the pharmacy operator’s stock after selling 2,630 shares during the period. Bronfman E.L. Rothschild L.P.’s holdings in CVS Health were worth $859,000 as of its most recent filing with the SEC.
Several other hedge funds also recently modified their holdings of CVS. Bank of New York Mellon Corp increased its stake in shares of CVS Health by 4.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 10,579,307 shares of the pharmacy operator’s stock worth $860,309,000 after purchasing an additional 481,262 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in shares of CVS Health by 1.5% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 238,668 shares of the pharmacy operator’s stock worth $19,408,000 after purchasing an additional 3,427 shares during the last quarter. Heritage Wealth Advisors increased its stake in shares of CVS Health by 21.2% during the 3rd quarter. Heritage Wealth Advisors now owns 4,979 shares of the pharmacy operator’s stock worth $406,000 after purchasing an additional 871 shares during the last quarter. Kwmg LLC increased its stake in shares of CVS Health by 6.8% during the 3rd quarter. Kwmg LLC now owns 20,140 shares of the pharmacy operator’s stock worth $1,638,000 after purchasing an additional 1,290 shares during the last quarter. Finally, Bedrijfstakpensioenfonds Voor DE Media PNO purchased a new stake in shares of CVS Health during the 3rd quarter worth approximately $3,484,000. Institutional investors own 83.96% of the company’s stock.
CVS Health opened at $65.76 on Friday, according to Marketbeat. The company has a market capitalization of $66.94 billion, a P/E ratio of 11.15, a price-to-earnings-growth ratio of 0.98 and a beta of 1.02. CVS Health has a 12 month low of $65.60 and a 12 month high of $66.34. The company has a quick ratio of 1.88, a current ratio of 2.37 and a debt-to-equity ratio of 1.59.
CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 2nd. The pharmacy operator reported $1.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.09. The company had revenue of $45.69 billion during the quarter, compared to the consensus estimate of $45.77 billion. CVS Health had a net margin of 3.59% and a return on equity of 17.45%. CVS Health’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the firm earned $1.17 EPS. equities analysts expect that CVS Health will post 6.99 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Thursday, May 3rd. Shareholders of record on Monday, April 23rd were issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 3.04%. The ex-dividend date was Friday, April 20th. CVS Health’s payout ratio is 33.90%.
In other news, Director C David Brown II purchased 10,000 shares of the business’s stock in a transaction on Friday, May 4th. The stock was purchased at an average cost of $61.99 per share, with a total value of $619,900.00. Following the acquisition, the director now directly owns 101,252 shares in the company, valued at $6,276,611.48. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 0.53% of the stock is owned by company insiders.
Several brokerages have recently issued reports on CVS. Needham & Company LLC set a $98.00 price target on shares of CVS Health and gave the stock a “buy” rating in a research note on Friday, February 9th. Leerink Swann set a $85.00 price target on shares of CVS Health and gave the stock a “buy” rating in a research note on Friday, February 9th. Citigroup set a $77.00 price target on shares of CVS Health and gave the stock a “neutral” rating in a research note on Tuesday, February 13th. ValuEngine lowered shares of CVS Health from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 8th. Finally, Bank of America began coverage on shares of CVS Health in a research note on Tuesday, February 27th. They set a “buy” rating and a $91.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. CVS Health has an average rating of “Buy” and a consensus price target of $86.27.
CVS Health Profile
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.